Uses for AI in Pharma R&D
AI is by far the biggest buzzword in pharma today - but unlike many other high-profile trends, AI has the potential to rapidly and totally transform the sector forever, speeding up processes, automating basic tasks and making sense of the...
4 years agoUses for AI in Pharma R&D
AI is by far the biggest buzzword in pharma today - but unlike many other high-profile trends, AI has the potential to rapidly and totally transform the sector forever, speeding up processes, automating basic tasks and making sense of the...
4 years ago
Weekly News Round-Up – 14/8/20
In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...
4 years agoWeekly News Round-Up – 14/8/20
In the news this week, the race for a vaccine begins to near its conclusion as the U.S. and U.K. continue to buy up supplies of promising vaccines, and Moderna comes under criticism for its steep prices that make the...
4 years ago
Key Challenges in Oncology and Bioinformatics
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...
4 years agoKey Challenges in Oncology and Bioinformatics
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...
4 years ago
The Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
4 years agoThe Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
4 years ago
Weekly News Round-up – 7/8/20
In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...
4 years agoWeekly News Round-up – 7/8/20
In the news this week, vaccine deals are afoot on either side of the Atlantic: both the U.K. and U.S. governments have signed deals with Sanofi and GSK for doses of their COVID-19 vaccine, while the UK has also requested...
4 years ago
Weekly News Round-up – 17/7/20
In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...
4 years agoWeekly News Round-up – 17/7/20
In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...
4 years ago
Weekly News Round-up – 10/7/20
In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....
4 years agoWeekly News Round-up – 10/7/20
In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....
4 years ago
Weekly News Round-up – 3/7/20
Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...
4 years agoWeekly News Round-up – 3/7/20
Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...
4 years ago
Weekly News Round-up – 19/6/20
This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...
4 years agoWeekly News Round-up – 19/6/20
This week, pharma begins looking beyond the imminent struggle against Covid-19’s initial challenges to the further horizon, and the dreaded second wave. Vaccine demand in a number of countries is rising in preparation of easing lockdowns, while Gilead’s remdesivir starts...
4 years ago
Weekly News Round-up – 5/6/20
The race for a COVID-19 vaccine continues, with AstraZeneca set to double potential capacity after a new deal struck with two companies supported by Bill and Melinda Gates. In other news, the WHO is set to restart trials for hydroxychloroquine,...
4 years agoWeekly News Round-up – 5/6/20
The race for a COVID-19 vaccine continues, with AstraZeneca set to double potential capacity after a new deal struck with two companies supported by Bill and Melinda Gates. In other news, the WHO is set to restart trials for hydroxychloroquine,...
4 years ago